In our study population, 78.3% of the patients with CF and 87.1% of the parents had no preexisting knowledge of the availability of DTC genetic testing for carrier status of genetic diseases ...
ReCode Therapeutics is set to secure up to $15m in additional funding from the Cystic Fibrosis Foundation to enhance its gene correction research programme. The initiative, conducted in ...
The Cystic Fibrosis Foundation is funding the development of a gene editing therapy that is designed to use ReCode’s tissue-specific delivery vehicle to transport gene editing cargo to the lung cells ...